AXSM — Axsome Therapeutics, Inc. stock price, charts and financials

Latest market price

217.01

+4.28+2.01%

Overview Short InterestFilings

AXSMQT72Axsome Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

217.01+2.01%

Earnings

Up 2.0% — Reported earnings — EPS missed by 49%, revenue in line.

High confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

SMMT+4.73%$14.62 TECH-0.23%$72.13 MDGL+0.69%$513.58 PRAX-0.32%$359.60 HALO-1.19%$101.89 BMRN+4.34%$66.58 ARWR+1.16%$88.67 ABVX-2.37%$127.82

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.73	Insider Own	3.83%	Shs Outstand	51.46M	Perf Week	-2.41%

Market Cap	10.95B	Forward P/E	39.11	EPS next Y	5.44	Insider Trans	-13.90%	Shs Float	43.56M	Perf Month	-14.55%

Enterprise Value	10.86B	PEG	-	EPS next Q	-	Inst Own	76.21%	Short Float	6.94%	Perf Quarter	-3.40%

Income	-189.39M	P/S	15.46	EPS this Y	38.42%	Inst Trans	-	Short Ratio	3.28	Perf Half Y	17.64%

Sales	708.24M	P/B	199.53	EPS next Y	336.82%	ROA	-26.39%	Short Interest	3.02M	Perf YTD	16.48%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-260.01%	52W High	265.43 -18.24%	Perf Year	106.02%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-50.29%	52W Low	103.93 108.81%	Perf 3Y	190.39%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	133.68% -	Gross Margin	92.60%	Volatility	3.31% 4.12%	Perf 5Y	337.83%

Dividend TTM	-	EV/Sales	15.34	EPS Y/Y TTM	37.73%	Oper. Margin	-24.80%	ATR (14)	9.16	Perf 10Y	2572.61%

Dividend Ex-Date	-	Quick Ratio	1.32	Sales Y/Y TTM	83.42%	Profit Margin	-26.59%	RSI (14)	37.62	Recom	2.04

Dividend Gr. 3/5Y	-	Current Ratio	1.39	EPS Q/Q	-57.50%	SMA20	-6.70%	Beta	0.70	Target Price	265.29

Payout	0.00%	Debt/Eq	4.03	Sales Q/Q	57.85%	SMA50	-10.01%	Rel Volume	1.12	Prev Close	212.74

Employees	925	LT Debt/Eq	1.91	Earnings	Aug 10	SMA200	13.57%	Avg Volume	845.89K	Price	217.01

IPO Date	Nov 19, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-49.21% -0.79%	Net Debt/EBITDA	0.49	Volume	947,795	Change	2.01%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-20-26	Initiated	BMO Capital	Outperform	$310
Jul-07-26	Reiterated	RBC Capital	Outperform	$302 → $304
Jun-11-26	Reiterated	Jefferies	Buy	$275 → $380
May-05-26	Reiterated	Deutsche Bank		$281 → $280
May-05-26	Reiterated	Robert W. Baird		$241 → $246
May-05-26	Reiterated	Needham	Buy	$225 → $267
May-05-26	Reiterated	Morgan Stanley	Equal Weight	$217 → $242
May-05-26	Reiterated	RBC Capital	Outperform	$222 → $302
May-05-26	Reiterated	HC Wainwright & Co.	Buy	$270 → $290
May-04-26	Reiterated	Oppenheimer		$250 → $280

Latest News

Today

Today10:30AM

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com

09:31AM

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimateszacks.com

09:05AM

Axsome Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

Aug-05-26

Aug-05-2610:16AM

Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metricszacks.com

Aug-03-26

Aug-03-2611:01AM

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out forzacks.com

Jul-31-26

Jul-31-2601:37PM

Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $306Benzinga

05:52AM

New Strong Sell Stocks for July 31stzacks.com

Jul-29-26

Jul-29-2606:31AM

New Strong Sell Stocks for July 29thzacks.com

Jul-27-26

Jul-27-2606:38AM

New Strong Sell Stocks for July 27thzacks.com

03:54AM

Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSMdefenseworld.net

Jul-22-26

Jul-22-2606:31AM

These major drug stocks rally after Trump's zero tariff announcementfinbold.com

Jul-21-26

Jul-21-2611:14AM

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For TuesdayBenzinga

Jul-16-26

Jul-16-2601:01PM

Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptancezacks.com

Jul-15-26

Jul-15-2601:14PM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price TargetBenzinga

07:00AM

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsyglobenewswire.com

Company

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Ownership

Total institutional ownership76.21%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	708	638	386	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	52	47	33	—	—	—	—	—	—
Gross Profit	656	591	352	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	634	571	411	—	—	—	—	—	—
Research and Development	192	183	187	—	—	—	—	—	—
Other Operating Expense	5	6	35	—	—	—	—	—	—
Operating Income	-175	-169	-281	—	—	—	—	—	—
Interest Expense	5	7	7	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-8	-8	0	—	—	—	—	—	—
Net Income Before Taxes	-189	-184	-287	—	—	—	—	—	—
Income Taxes	-1	-1	0	—	—	—	—	—	—
Consolidated Net Income	-189	-183	-287	—	—	—	—	—	—
Net Income From Continuing Operations	-189	-183	-287	—	—	—	—	—	—
Net Income	-189	-183	-287	—	—	—	—	—	—
EPS (Recurring)	-3.73	-3.68	-5.99	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.73	-3.68	-5.99	—	—	—	—	—	—
EPS (Diluted)	-3.73	-3.68	-5.99	—	—	—	—	—	—
EBITDA	-173	-168	-273	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	15.63	14.31	10.52	—	—	—	—	—	—
Gross Margin	92.66	92.63	91.19	—	—	—	—	—	—
Operating Margin	-24.72	-26.49	-72.80	—	—	—	—	—	—
Net Margin	-26.69	-28.68	-74.35	—	—	—	—	—	—
Shares Outstanding	51	50	48	—	—	—	—	—	—
Market Capitalization	11,068	9,132	4,061	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TABUTEAU HERRIOT	Chief Executive Officer	Aug 06 '26	Sale	213.95	4,660	997,007	7,229	Aug 07
TABUTEAU HERRIOT	Chief Executive Officer	Aug 06 '26	Option Exercise	4.95	4,660	23,067	11,889	Aug 07
TABUTEAU HERRIOT	Chief Executive Officer	Aug 05 '26	Sale	212.01	45,004	9,541,298	7,229	Aug 07
TABUTEAU HERRIOT	Chief Executive Officer	Aug 05 '26	Option Exercise	4.95	45,004	222,770	52,233	Aug 07
TABUTEAU HERRIOT	Chief Executive Officer	Jul 01 '26	Option Exercise	4.95	49,666	245,847	56,895	Jul 01
TABUTEAU HERRIOT	Chief Executive Officer	Jul 01 '26	Sale	240.25	49,666	11,932,257	7,229	Jul 01
JEFFS ROGER	Director	Jun 11 '26	Sale	249.12	286	71,248	58,367	Jun 11
JEFFS ROGER	Director	Jun 10 '26	Sale	246.18	286	70,407	58,653	Jun 11
Coleman Mark	Director	Jun 10 '26	Sale	249.00	643	160,107	30,389	Jun 10
Mahony Susan	Director	Jun 10 '26	Sale	246.18	300	73,854	829	Jun 10
Mahony Susan	Director	Jun 09 '26	Sale	237.21	300	71,163	1,129	Jun 10
Mahony Susan	Director	Jun 08 '26	Option Exercise	0.00	1,429	0	1,429	Jun 10
JEFFS ROGER	Director	Jun 08 '26	Option Exercise	0.00	1,429	0	58,939	Jun 10
Coleman Mark	Director	Jun 08 '26	Option Exercise	0.00	1,429	0	31,032	Jun 10
Saad Mark E	Director	Jun 08 '26	Option Exercise	0.00	1,429	0	11,431	Jun 10

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.